Fresenius Medical Care Boosts Investment in Value-Based Care
Fresenius Medical Care, a leader in products and services for individuals with renal diseases, is making significant strides in its commitment to Value-Based Care (VBC). By investing EUR 312 million and concluding a share purchase agreement with non-physician investors in Interwell Health, the company is accelerating the implementation originally anticipated during its mergers.
Key Developments in the Value-Based Care Strategy
With the recent investments, Fresenius Medical Care marks a notable evolution in its FME Reignite strategy, which aims to enhance value for stakeholders through core strengthening, innovation, and culture development. The company's unique structure integrates VBC alongside Care Delivery and Enablement, thereby driving growth while lowering costs and establishing industry standards.
Investment Highlights
The closing of this share purchase agreement is a historic move, significantly increasing Fresenius's ownership stake in Interwell Health. The transaction enhances its role within the renal VBC sector, allowing partnerships with over 2,200 nephrologists across the United States, and generating impressive revenues. In the first half of the year, the revenue reported was EUR 1,035 million, reflecting a robust growth of 23.5%.
Leadership Transition to Propel Growth
Fresenius Medical Care has also announced an important leadership change. Tommy P. O'Connor is set to take over as CEO of Interwell Health effective from October 1, 2025. His background in healthcare leadership, particularly with United Healthcare, positions him well to foster growth and operational excellence within the VBC segment.
Future Directions
Helen Giza, CEO of Fresenius Medical Care, emphasized that this great investment and leadership appointment place the company firmly on the path to improving patient outcomes and reducing care costs. Tommy O'Connor's vision aligns closely with the company's aspirations as he leads efforts in innovating patient-centered care models.
As FME expands its capabilities in renal care, the focus will remain on leveraging its vast resources and efficiencies, a core aspect of its ambitious FME Reignite strategy. This holistic approach is predicted to unlock new potentials for growth while firmly aligning with partners and improving healthcare delivery systems.
About Fresenius Medical Care
Fresenius Medical Care holds a prominent position as the premier provider of renal care products and services globally, catering to approximately 4.2 million individuals requiring regular dialysis treatment. With an extensive network of 3,676 dialysis clinics, it serves about 300,000 patients worldwide, along with offering advanced dialysis products.
Frequently Asked Questions
What is the focus of Fresenius Medical Care's recent investment?
The investment primarily aims to enhance its Value-Based Care strategy and expand its leadership in the kidney health sector.
Who has been appointed as the new CEO of Interwell Health?
Tommy P. O'Connor has been named the new CEO of Interwell Health, taking charge from October 1, 2025, following Robert Sepucha.
How does Fresenius Medical Care plan to improve patient outcomes?
The company aims to progress by leveraging its integrated structure in renal care to accelerate innovation and reduce overall costs.
What makes Interwell Health a leader in the VBC industry?
Interwell Health has established partnerships with over 2,200 nephrologists, driving robust revenue growth and focusing on renal value-based strategies.
What are the strategic priorities of Fresenius Medical Care's FME Reignite strategy?
The strategic priorities include strengthening the core business, driving growth and innovation, and fostering a positive company culture.
